10 Best Dividend Growth Stocks Insiders Are Buying for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In a market environment marked by volatility and shifting sector leadership, ValueSense’s quantitative and qualitative screening tools help investors identify stocks with strong fundamentals, attractive valuations, and sustainable growth prospects[1]. Our selection process emphasizes:
- Intrinsic Value: Each stock is evaluated using ValueSense’s proprietary blended valuation models, including discounted cash flow (DCF) and relative valuation, to estimate true worth beyond market price[1].
- Quality Metrics: We screen for high return on invested capital (ROIC), robust free cash flow margins, and manageable debt levels.
- Sector Diversification: The watchlist spans semiconductors, healthcare, energy, industrials, and utilities to balance risk and opportunity.
- Recent Performance: We consider both recent returns and long-term growth potential, highlighting stocks that may be overlooked due to short-term headwinds.
This methodology ensures a balanced, data-driven approach to stock selection, suitable for investors seeking both growth and value[1].
Featured Stock Analysis
Stock #1: Applied Materials, Inc. (AMAT)
| Metric | Value |
|---|---|
| Market Cap | $188.1B |
| Quality Rating | 7.1 |
| Intrinsic Value | $242.0 |
| 1Y Return | 29.0% |
| Revenue | $28.6B |
| Free Cash Flow | $5,861.0M |
| Revenue Growth | 6.6% |
| FCF margin | 20.5% |
| Gross margin | 48.5% |
| ROIC | 35.3% |
| Total Debt to Equity | 34.7% |
Investment Thesis
Applied Materials stands out in the semiconductor equipment sector with a market cap of $188.1 billion and a quality rating of 7.1. The company’s intrinsic value of $242.0 suggests significant upside potential relative to its current market price. AMAT delivered a 29.0% one-year return, driven by $28.6 billion in revenue and $5.9 billion in free cash flow. Its revenue growth of 6.6% and industry-leading ROIC of 35.3% reflect operational excellence and a strong competitive position. The gross margin of 48.5% and free cash flow margin of 20.5% further underscore its profitability, while a moderate debt-to-equity ratio of 34.7% indicates a solid balance sheet.
Key Catalysts
- Continued global semiconductor demand and capital expenditure cycles
- Leadership in advanced chip manufacturing equipment
- Strong free cash flow generation supporting dividends and buybacks
Risk Factors
- Cyclicality in semiconductor capital spending
- Geopolitical risks affecting global supply chains
- Intense competition from global peers
Stock #2: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $140.1B |
| Quality Rating | 6.3 |
| Intrinsic Value | $39.3 |
| 1Y Return | -10.1% |
| Revenue | $63.8B |
| Free Cash Flow | $12.4B |
| Revenue Growth | 14.7% |
| FCF margin | 19.5% |
| Gross margin | 66.2% |
| ROIC | 10.6% |
| Total Debt to Equity | 69.4% |
Investment Thesis
Pfizer, a healthcare giant with a $140.1 billion market cap, offers a quality rating of 6.3 and an intrinsic value of $39.3. Despite a -10.1% one-year return, the company posted $63.8 billion in revenue and $12.4 billion in free cash flow, with revenue growth accelerating to 14.7%. Pfizer’s gross margin of 66.2% and free cash flow margin of 19.5% highlight its profitability, though ROIC of 10.6% is modest for the sector. The debt-to-equity ratio of 69.4% is elevated but manageable given its cash flow.
Key Catalysts
- Diversified pharmaceutical pipeline beyond COVID-19 vaccines
- Strong cash flow supporting dividend stability
- Strategic acquisitions and partnerships in oncology and rare diseases
Risk Factors
- Patent expirations on key drugs
- Regulatory and pricing pressures
- Integration risks from recent acquisitions
Stock #3: ConocoPhillips (COP)
| Metric | Value |
|---|---|
| Market Cap | $111.7B |
| Quality Rating | 5.9 |
| Intrinsic Value | $113.5 |
| 1Y Return | -17.6% |
| Revenue | $58.3B |
| Free Cash Flow | $6,923.0M |
| Revenue Growth | 3.5% |
| FCF margin | 11.9% |
| Gross margin | 28.7% |
| ROIC | 9.3% |
| Total Debt to Equity | 35.9% |
Investment Thesis
ConocoPhillips, with a $111.7 billion market cap and a quality rating of 5.9, has an intrinsic value of $113.5. The stock declined -17.6% over the past year, but the company generated $58.3 billion in revenue and $6.9 billion in free cash flow. Revenue growth of 3.5% and a free cash flow margin of 11.9% reflect resilience in a volatile energy market. The gross margin of 28.7% and ROIC of 9.3% are solid for the sector, while a debt-to-equity ratio of 35.9% indicates prudent leverage.
Key Catalysts
- Exposure to global energy demand recovery
- Strong free cash flow supporting shareholder returns
- Strategic positioning in low-cost oil and gas basins
Risk Factors
- Commodity price volatility
- Transition risks amid global decarbonization
- Operational risks in exploration and production
Stock #4: Cintas Corporation (CTAS)
| Metric | Value |
|---|---|
| Market Cap | $73.9B |
| Quality Rating | 6.8 |
| Intrinsic Value | $77.9 |
| 1Y Return | -10.6% |
| Revenue | $10.6B |
| Free Cash Flow | $1,695.7M |
| Revenue Growth | 8.2% |
| FCF margin | 16.1% |
| Gross margin | 50.1% |
| ROIC | 27.8% |
| Total Debt to Equity | 45.9% |
Investment Thesis
Cintas, a leader in uniform and facility services, boasts a $73.9 billion market cap and a quality rating of 6.8. Its intrinsic value of $77.9 suggests potential upside. Despite a -10.6% one-year return, the company posted $10.6 billion in revenue and $1.7 billion in free cash flow, with revenue growth of 8.2%. A gross margin of 50.1% and ROIC of 27.8% highlight operational efficiency, though the debt-to-equity ratio of 45.9% is above the sector average.
Key Catalysts
- Recurring revenue model with high customer retention
- Cross-selling opportunities in safety and facility services
- Margin expansion through operational improvements
Risk Factors
- Economic sensitivity to business cycles
- Rising labor and material costs
- Competitive pressures in fragmented markets
Stock #5: Elevance Health Inc. (ELV)
| Metric | Value |
|---|---|
| Market Cap | $71.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $295.5 |
| 1Y Return | -21.2% |
| Revenue | $194.8B |
| Free Cash Flow | $3,767.0M |
| Revenue Growth | 12.0% |
| FCF margin | 1.9% |
| Gross margin | 77.7% |
| ROIC | 14.7% |
| Total Debt to Equity | 2.1% |
Investment Thesis
Elevance Health, a managed care leader, has a $71.6 billion market cap and a quality rating of 6.1. Its intrinsic value of $295.5 is well above the current price, despite a -21.2% one-year return. The company generated $194.8 billion in revenue and $3.8 billion in free cash flow, with revenue growth of 12.0%. A gross margin of 77.7% and ROIC of 14.7% are strong, while a minimal debt-to-equity ratio of 2.1% reflects financial prudence.
Key Catalysts
- Growth in government-sponsored healthcare programs
- Diversification into pharmacy benefits and care delivery
- Strong cash flow supporting buybacks and dividends
Risk Factors
- Regulatory changes in healthcare reimbursement
- Rising medical cost trends
- Integration risks from acquisitions
Stock #6: Enterprise Products Partners L.P. (EPD)
| Metric | Value |
|---|---|
| Market Cap | $67.4B |
| Quality Rating | 5.3 |
| Intrinsic Value | $104.9 |
| 1Y Return | 9.1% |
| Revenue | $54.8B |
| Free Cash Flow | $4,211.0M |
| Revenue Growth | 0.0% |
| FCF margin | 7.7% |
| Gross margin | 13.1% |
| ROIC | 10.2% |
| Total Debt to Equity | 109.4% |
Investment Thesis
Enterprise Products, a midstream energy leader, has a $67.4 billion market cap and a quality rating of 5.3. Its intrinsic value of $104.9 suggests upside, with a 9.1% one-year return. The company posted $54.8 billion in revenue and $4.2 billion in free cash flow, though revenue growth was flat. A gross margin of 13.1% and ROIC of 10.2% are solid for the sector, but the debt-to-equity ratio of 109.4% is high.
Key Catalysts
- Fee-based cash flows from critical energy infrastructure
- Attractive distribution yield
- Strategic expansion in natural gas liquids
Risk Factors
- Exposure to energy commodity cycles
- High leverage relative to peers
- Regulatory and environmental risks
Stock #7: CSX Corporation (CSX)
| Metric | Value |
|---|---|
| Market Cap | $67.1B |
| Quality Rating | 6.4 |
| Intrinsic Value | $37.5 |
| 1Y Return | 7.9% |
| Revenue | $15.0B |
| Free Cash Flow | $3,777.0M |
| Revenue Growth | 2.1% |
| FCF margin | 25.2% |
| Gross margin | 36.6% |
| ROIC | 18.8% |
| Total Debt to Equity | 12.3% |
Investment Thesis
CSX, a leading North American railroad, has a $67.1 billion market cap and a quality rating of 6.4. Its intrinsic value of $37.5 is close to the current price, with a 7.9% one-year return. The company generated $15.0 billion in revenue and $3.8 billion in free cash flow, with revenue growth of 2.1%. A free cash flow margin of 25.2% and ROIC of 18.8% are impressive, while a low debt-to-equity ratio of 12.3% reflects financial strength.
Key Catalysts
- Pricing power in a consolidated industry
- Efficiency gains from precision scheduled railroading
- Exposure to industrial and intermodal growth
Risk Factors
- Economic sensitivity to freight volumes
- Labor and regulatory challenges
- Competition from trucking and other railroads
Stock #8: Energy Transfer LP (ET)
| Metric | Value |
|---|---|
| Market Cap | $57.8B |
| Quality Rating | 5.8 |
| Intrinsic Value | $47.3 |
| 1Y Return | 5.7% |
| Revenue | $80.6B |
| Free Cash Flow | $10.6B |
| Revenue Growth | (3.7%) |
| FCF margin | 13.1% |
| Gross margin | 18.2% |
| ROIC | 8.1% |
| Total Debt to Equity | 134.3% |
Investment Thesis
Energy Transfer, a diversified midstream operator, has a $57.8 billion market cap and a quality rating of 5.8. Its intrinsic value of $47.3 suggests modest upside, with a 5.7% one-year return. The company posted $80.6 billion in revenue and $10.6 billion in free cash flow, though revenue declined -3.7%. A free cash flow margin of 13.1% and ROIC of 8.1% are reasonable, but the debt-to-equity ratio of 134.3% is a concern.
Key Catalysts
- Extensive pipeline and storage network
- Attractive distribution yield
- Growth in natural gas and NGL volumes
Risk Factors
- High leverage and interest rate sensitivity
- Regulatory and environmental scrutiny
- Volatility in energy markets
Stock #9: Occidental Petroleum Corporation (OXY)
| Metric | Value |
|---|---|
| Market Cap | $40.6B |
| Quality Rating | 5.6 |
| Intrinsic Value | $34.7 |
| 1Y Return | -17.0% |
| Revenue | $27.2B |
| Free Cash Flow | $4,896.0M |
| Revenue Growth | 0.1% |
| FCF margin | 18.0% |
| Gross margin | 34.9% |
| ROIC | 3.5% |
| Total Debt to Equity | 66.8% |
Investment Thesis
Occidental Petroleum, an integrated energy company, has a $40.6 billion market cap and a quality rating of 5.6. Its intrinsic value of $34.7 is close to the current price, with a -17.0% one-year return. The company generated $27.2 billion in revenue and $4.9 billion in free cash flow, with flat revenue growth. A free cash flow margin of 18.0% is strong, but ROIC of 3.5% is low, and the debt-to-equity ratio of 66.8% is elevated.
Key Catalysts
- Leadership in Permian Basin production
- Carbon capture and sequestration initiatives
- Strong free cash flow supporting debt reduction
Risk Factors
- Oil price volatility
- High leverage and interest expense
- Transition risks in energy markets
Stock #10: Eversource Energy (ES)
| Metric | Value |
|---|---|
| Market Cap | $27.2B |
| Quality Rating | 5.6 |
| Intrinsic Value | $86.9 |
| 1Y Return | 13.5% |
| Revenue | $13.0B |
| Free Cash Flow | ($1,013.4M) |
| Revenue Growth | 14.4% |
| FCF margin | (7.8%) |
| Gross margin | 50.1% |
| ROIC | 4.6% |
| Total Debt to Equity | 188.2% |
Investment Thesis
Eversource Energy, a regulated utility, has a $27.2 billion market cap and a quality rating of 5.6. Its intrinsic value of $86.9 suggests upside, with a 13.5% one-year return. The company posted $13.0 billion in revenue, but free cash flow was negative at -$1.0 billion. Revenue growth of 14.4% is strong, but the free cash flow margin of -7.8% and ROIC of 4.6% are weak. The debt-to-equity ratio of 188.2% is very high.
Key Catalysts
- Stable regulated earnings
- Investment in renewable energy infrastructure
- Geographic footprint in high-growth Northeast markets
Risk Factors
- High leverage and interest rate sensitivity
- Regulatory lag in rate recovery
- Weather-related operational risks
Portfolio Diversification Insights
This watchlist spans semiconductors (AMAT), healthcare (PFE, ELV), energy (COP, EPD, ET, OXY), industrials (CTAS, CSX), and utilities (ES), offering broad sector exposure. Such diversification helps mitigate sector-specific risks while capturing growth across the economy. High-quality, cash-generative companies like AMAT and CTAS balance more cyclical names in energy and healthcare, while regulated utilities like ES provide defensive characteristics.
Market Timing & Entry Strategies
Given mixed one-year returns and varying intrinsic value estimates, investors may consider dollar-cost averaging into positions, especially for stocks trading below their calculated intrinsic value. Monitoring quarterly earnings, macroeconomic trends, and sector-specific catalysts can help identify optimal entry points. ValueSense’s backtesting and screening tools allow investors to validate strategies before committing capital[1].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
These stocks were selected using ValueSense’s quantitative screening for intrinsic value, quality, and growth metrics, combined with sector diversification to balance risk and opportunity[1].
Q2: What's the best stock from this list?
There is no single “best” stock—each offers unique risk/reward profiles. Applied Materials (AMAT) and Cintas (CTAS) stand out for quality and growth, while Pfizer (PFE) and Elevance Health (ELV) offer defensive characteristics. The right choice depends on your investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification is key to managing risk. This watchlist is designed to provide exposure across sectors, but investors should tailor allocations based on individual research and portfolio needs.
Q4: What are the biggest risks with these picks?
Risks include sector cyclicality (energy, semiconductors), regulatory changes (healthcare, utilities), leverage (midstream energy, utilities), and macroeconomic headwinds affecting growth and margins.
Q5: When is the best time to invest in these stocks?
Consider gradual entry during market pullbacks or when stocks trade below intrinsic value. Use ValueSense’s tools to monitor valuation, earnings trends, and macroeconomic signals for timing[1].